Lyell Immunopharma, Inc. (LYEL) › Shareholders' EquityLyell Immunopharma, Inc. (LYEL) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2018: $850.0K2019: -$111.11M2020: -$292.53M2021: $929.79M2022: $833.25M2023: $654.95M2024: $382.82M2025: $248.20M$248.20M2018Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$248.20M-35.2%2024$382.82M-41.5%2023$654.95M-21.4%2022$833.25M-10.4%2021$929.79M+417.8%2020-$292.53M-163.3%2019-$111.11M-13171.5%2018$850.0K—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share